Pharmaceutical Executive, December 2022 Issue (PDF)

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor antagonist for patients with Tourette syndrome.

The YouScript CEO discusses new FDA guidance.